Book a demo
Boehringer Ingelheim v. Granules India — Linagliptin ANDA Patent Consent Judgment | PatSnap
Explore in Eureka
Case ID1:24-cv-00753
FiledJun 2024
ClosedOct 2024
Patent Litigation

Boehringer Ingelheim v. Granules India: Linagliptin ANDA Blocked by Consent Judgment

Boehringer Ingelheim and its affiliates sued Granules India in Delaware over two linagliptin patents covering a 5 mg tablet formulation. The case resolved in just 113 days when Granules agreed to a consent judgment — conceding patent validity and accepting an injunction barring its ANDA product until both patents expire, including any term extensions.

Resolution time
113days
113 days — faster than the median ANDA Hatch-Waxman resolution in Delaware District Court
Patents asserted
2
US9486526B2 and 1 further patent asserted — linagliptin 5 mg tablet formulation and methods of use
Outcome
Consent Judgment
Granules conceded validity; injunction runs through patent expiry including any term extension
Cost ruling
No Costs Awarded
Dismissed without costs, disbursements, or attorney fees to either party per consent judgment terms
Published by PatSnap Insights Team · Verified by PatSnap Eureka Data
Case overview

Granules India yields early: linagliptin ANDA blocked through patent expiry

In June 2024, Boehringer Ingelheim Corporation, Boehringer Ingelheim Pharma GmbH & Co. KG, and Boehringer Ingelheim International GmbH filed a Hatch-Waxman ANDA infringement action in the District of Delaware against Granules India Limited. The suit asserted two patents — US9486526B2 and US10034877B2 — covering linagliptin 5 mg tablets, the active ingredient in Tradjenta, a widely prescribed type-2 diabetes treatment. Granules’ ANDA No. 219466 had triggered the statutory 30-month stay and the litigation.

The case closed on 16 October 2024 via a consent judgment entered by Judge Colm F. Connolly — just 113 days after filing. Under the consent judgment, Granules expressly agreed that both the ‘526 and ‘877 patents are valid and enforceable, and accepted a permanent injunction preventing it from making, using, selling, importing, or distributing its ANDA product until expiry of both patents, including any patent term extension or adjustment. All remaining claims were dismissed without prejudice and without costs to either party.

A resolution in under four months is notably swift even by Hatch-Waxman standards and suggests Granules assessed litigation risk unfavourably — potentially after reviewing claim scope, prosecution history, or prior failed challenges to these patents. The public record does not disclose whether a confidential licence or authorised-generic agreement accompanies the consent judgment, which is common in ANDA settlements and would materially affect Granules’ commercial upside. The absence of a costs award is consistent with a negotiated exit rather than a contested defeat.

Case at a glance
Case no.1:24-cv-00753
CourtDelaware
JudgeColm F. Connolly
FiledJune 25, 2024
ClosedOctober 16, 2024
Duration113 days
OutcomeConsent Judgment
Verdict causeInfringement Action
BasisConsent Judgment
Prior Art Intelligence
See what prior art exists on this patent.
Eureka scans millions of patents and papers to surface prior art that may have invalidated these claims before costly litigation begins.
Check Prior Art
Case data sourced from PACER / Delaware District Court via PatSnap Eureka Litigation Intelligence Explore similar cases ↗
Case timeline

Filing to Consent Judgment in 113 days

113 days — faster than the median ANDA Hatch-Waxman resolution in Delaware District Court

Case timeline: Complaint filed JUN 25 2024, AUG–SEP — 113 days total Horizontal timeline showing the three key events in Boehringer-Ingelheim v Granules India Limited from filing to resolution. Source: PACER, Delaware District Court. JUN 25 2024 Complaint filed Pre-trial proceedings OCT 16 2024 Consent Judgment 113 DAYS TOTAL
Dismissal terms

Consent judgment entered: what the Granules India order means for both parties

Legal mechanism

What a consent judgment means in Hatch-Waxman litigation

A consent judgment is a court-ordered agreement where the defendant concedes specified facts and accepts binding relief without a full trial. Here, Granules expressly admitted that both asserted patents are valid and enforceable — a significant concession. The court retains jurisdiction to enforce the order, and any future breach exposes Granules to contempt proceedings in Delaware.

Binding admission of validity
Patent holder outcome

Boehringer secures injunction through full patent term

The consent judgment delivers Boehringer its commercially critical objective: Granules’ ANDA product is blocked until both the ‘526 and ‘877 patents expire, including any patent term extension. Boehringer also preserved the right to seek court modification if it obtains additional regulatory exclusivities — a forward-looking protection. No costs were awarded, but the speed and completeness of the win suggests minimal litigation spend.

Full-term market exclusivity protected
Generic challenger outcome

Granules’ ANDA blocked; no admitted licence disclosed

Granules accepted an injunction of potentially years in duration and conceded patent validity, foreclosing the ability to re-litigate those questions in this court. Critically, the public record does not confirm whether a confidential authorised-generic or licence arrangement was agreed — a common feature of ANDA consent judgments that could preserve some commercial value for Granules. Absent such a deal, market entry is deferred until patent expiry.

Market entry deferred to patent expiry
Commercial implications

Linagliptin IP position strengthened against future ANDA filers

Granules’ admission of validity strengthens Boehringer’s litigation posture against any subsequent ANDA challengers to these two patents. Other generic manufacturers monitoring this docket will note that Boehringer obtained a full consent judgment in under four months. For competitors developing linagliptin generics, this outcome signals that challenging the ‘526 and ‘877 patents without strong prior art or validity arguments carries elevated settlement risk.

Higher bar for future generic challengers
Legal analysis based on PACER docket records for case 1:24-cv-00753 and PatSnap Eureka litigation intelligence Search PatSnap Eureka ↗
Parties and representation

Full party and counsel information

RoleNameTypeDetail
PlaintiffBoehringer-IngelheimIndividualPharmaceutical innovator — holder of US9486526B2 and US10034877B2 covering linagliptin tabletsSearch in Eureka ↗
Co-PlaintiffBoehringer Ingelheim CorporationCompanySearch in Eureka ↗
Co-PlaintiffBoehringer Ingelheim Pharma Gmbh & Co., KGCompanySearch in Eureka ↗
Co-PlaintiffBoehringer Ingelheim International, GMBHCompanySearch in Eureka ↗
DefendantGranules India LimitedIndividualGranules India Limited — generic pharmaceutical manufacturer seeking ANDA approval for linagliptin 5 mg tabletsSearch in Eureka ↗
Plaintiff counselBrian P. EganAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff counselJack B. BlumenfeldAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff counselMegan Elizabeth DellingerAttorneyCounsel for Boehringer-IngelheimSearch in Eureka ↗
Plaintiff law firmMorris, Nichols, Arsht & Tunnell LLPLaw FirmRepresenting Boehringer-IngelheimSearch in Eureka ↗
Presiding judgeJudge Colm F. ConnollyJudgeDelaware District CourtSearch in Eureka ↗
Official verdict

Official order — verbatim text

“This Court has jurisdiction over the subject matter of this action and 2. 3. IT IS HEREBY ORDERED, ADJUDGED AND DECREED that: 1. has personal jurisdiction over the parties. As used in this Consent Judgment, (i) the term "the ‘526 Patent" means U.S. Patent No. 9,486,526, which Granules agrees is valid and enforceable, (ii) the term "the ‘877 Patent" means U.S. Patent No. 10,034,877, which Granules agrees is valid and enforceable, (iii) the term "Granules ANDA Product" shall mean Granules’ ANDA No. 219466 together with any supplements, amendments, or replacements thereto, and (iv) the term "Affiliate" shall mean any entity controlling, controlled by, or under common control with a Party, but only as long as such control continues, where "control" means: (1) the ownership of at least fifty percent (50%) of the equity or beneficial interest of such entity, or the right to vote for or appoint a majority of the board of directors or other governing body of such entity; or (2) the power to directly or indirectly direct or cause the direction of the management and policies of such entity by any means whatsoever. Unless specifically authorized or otherwise modified between the parties, Granules, including any of its successors and assigns, is enjoined from making, having made, using, selling, offering to sell, importing or distributing the Granules ANDA Product, on its own part or through any Affiliate, officer, agent, servant, employee or attorney, or through any person in concert or coordination with 5. 6. 7. Granules or its Affiliates, through and until the expiration of the ‘526 Patent and the ‘877 Patent, including any patent term extension and/or patent term adjustment. If Bochringer becomes entitled to any other regulatory exclusivities that are not referenced herein, Bochringer may apply to the Court for modification of the consent judgment to incorporate such specified exclusivity. 4. The Parties agree that, in the event of violation of the terms of this Consent Judgment or any related agreement(s), jurisdiction and venue for an action to enforce performance under this Consent Judgment, including for a preliminary injunction against the breaching conduct, exists in this District Court, and the Parties hereby waive any and all defenses based on personal jurisdiction and venue. Nothing herein prohibits or is intended to prohibit Granules from maintaining and/or (e.g, in the case of a recertification pursuant to 21 C.F.R.§ 314.96(d)) filing a "Paragraph IV Certification" pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV) or pursuant to 21 C.F.R. § 314.94(a)(12) with respect to the ‘526 Patent or the ‘877 Patent. This Court retains jurisdiction to enforce or supervise performance under this Consent Judgment and any related agreement(s). The Complaint and all remaining claims, counterclaims, or affirmative defenses in the above action are dismissed without prejudice and without costs, disbursements, or attorney fees to any party.”
Source: PACER Docket, Case 1:24-cv-00753, Delaware District Court

The consent judgment is notable for the breadth of Granules’ concessions: it admits validity and enforceability of both asserted patents by name, accepts an injunction running to expiry including term extensions, and waives jurisdictional defences for enforcement actions. The without-prejudice dismissal of all remaining claims is procedurally standard in ANDA consent judgments and does not indicate any weakness in Boehringer’s infringement position — it simply preserves procedural flexibility. The court’s explicit retention of jurisdiction to supervise performance signals that compliance monitoring was a priority for Boehringer.

PACER case 1:24-cv-00753 · Public docket record Explore in Eureka ↗
Patent at issue

US9486526B2 & US10034877B2 — linagliptin tablet formulation patents

Publication No.US10034877B2
Application No.US15/287228
Patent details
ProductLinagliptin tablet formulations and methods of use for type-2 diabetes treatment
Cited in actionJune 25, 2024

Publication No.US9486526B2
Application No.US14/294630
Patent details
ProductLinagliptin pharmaceutical compositions and dosage forms including 5 mg tablets
Cited in actionJune 25, 2024

US9486526B2 (application no. US14/294630) and US10034877B2 (application no. US15/287228) both protect aspects of linagliptin — a DPP-4 inhibitor used to treat type-2 diabetes and marketed as Tradjenta. The patents cover formulations and methods related to the 5 mg tablet dosage form. Their assertion in an ANDA context means Boehringer listed them in the FDA’s Orange Book, triggering mandatory Paragraph IV certification by any generic seeking early entry, and the associated 30-month stay of ANDA approval.

For the branded pharmaceutical sector, Orange Book-listed patents on a high-volume diabetes medication represent substantial commercial value. Linagliptin competes in the DPP-4 inhibitor class alongside sitagliptin and saxagliptin, making generic entry commercially significant for both Boehringer and the generic manufacturer. The consent judgment’s admission of validity now forms part of the public record, which future ANDA challengers and inter partes review petitioners will need to contend with when assessing the litigation risk of challenging either patent.

Patent data sourced from USPTO via PatSnap Eureka patent database Search patent records in Eureka ↗
Freedom to operate

Should you run an FTO analysis against US9486526B2 and US10034877B2?

Any pharmaceutical developer formulating linagliptin-containing products — including combination tablets, modified-release forms, or alternative dosage strengths — should assess freedom to operate against both Orange Book-listed patents. The consent judgment confirms enforceability and validity, removing the most common defensive arguments. R&D teams working on DPP-4 inhibitor generics or follow-on formulations face meaningful infringement risk if their product falls within the claim scope of either patent.

PatSnap Eureka’s FTO Search Agent can map your formulation against the claim landscapes of US9486526B2 and US10034877B2, identify prosecution history estoppel constraints, and flag related continuation or divisional patents in Boehringer’s linagliptin portfolio. Early FTO analysis reduces the cost of reformulation or design-around work and helps prioritise which Orange Book patents represent the highest litigation exposure before an ANDA is filed.

PatSnap Eureka FTO Search

Run a freedom-to-operate analysis on US10034877B2 to assess your product’s exposure

Run FTO in Eureka →
Related litigation

Similar ANDA linagliptin and DPP-4 inhibitor patent cases in Delaware

These cases involve ANDA patent infringement actions over DPP-4 inhibitor and diabetes drug formulations litigated in Delaware District Court, comparable to this dispute.

🔍
Access 40+ similar cases in PatSnap Eureka
Boehringer-Ingelheim patent enforcement history, Delaware case history, Boehringer-Ingelheim’s full IP portfolio, and comparable case analysis
Tradjenta ANDA prior suitsDPP-4 inhibitor consent judgmentsBoehringer Orange Book litigationDelaware ANDA 30-month stay cases
Unlock similar cases in Eureka →
Strategic implications

What this case signals for the diabetes drug ANDA IP landscape

A sub-120-day consent judgment with patent validity conceded sets a clear precedent for how Boehringer defends its linagliptin franchise.

Early consent signals strong patent position on linagliptin formulations

Granules’ decision to concede validity of both patents within 113 days — before substantive motions practice — suggests either a weak invalidity case or an unfavourable freedom-to-operate assessment. Generic developers targeting linagliptin should conduct thorough prior-art analysis against the ‘526 and ‘877 patents before filing an ANDA with Paragraph IV certifications.

No-costs dismissal may conceal a confidential licence arrangement

ANDA consent judgments without costs and with preservation of Paragraph IV certification rights are frequently paired with undisclosed authorised-generic or licence agreements. The explicit retention of Granules’ Paragraph IV rights in the order — while also imposing an injunction — is structurally consistent with a delayed entry licence. IP teams tracking the linagliptin competitive landscape should monitor Granules’ ANDA status with the FDA.

🔒
Full strategic analysis in PatSnap Eureka
Unlock full strategic analysis for the linagliptin ANDA sector including PTE risk, licence probability, and Delaware District Court enforcement patterns.
PTE extension risk mapAuthorised-generic probabilityJudge Connolly ANDA patterns
Unlock full analysis →
Analysis powered by PatSnap Eureka Litigation Intelligence Explore in Eureka ↗
Frequently asked questions

Boehringer-Ingelheim v Granules — key questions answered

Still have questions? PatSnap Eureka can answer them instantly from patent and litigation data. Ask Eureka ↗
PatSnap Eureka

Track linagliptin ANDA filings and DPP-4 patent enforcement in real time

Monitor new ANDA challenges to Boehringer’s linagliptin patents and run FTO assessments against the ‘526 and ‘877 patents using PatSnap Eureka’s litigation intelligence and patent analytics tools.

Ask anything about this case.
PatSnap Eureka searches patents and litigation data to answer instantly.
Powered by PatSnap Eureka
Link copied to clipboard

Help us improve this page

Found incorrect or outdated information? Let us know and we'll get it fixed.